MC
SCPS

Moors & Cabot’s Scopus BioPharma Inc. Common Stock SCPS Stock Holding History

Moors & Cabot’s Portfolio SCPS Stock Details SCPS Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2022
Q2 		– Sell
-14,500
Closed -$10K – 936
2022
Q1 		$10K Buy
+14,500
New +$14K ﹤0.01% 860

Other funds holding SCPS

Geode Capital Management
Geode Capital Management Boston, Massachusetts $1.61T AUM 30.72% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $63.9B AUM 45.56% 1-Year Est. Return
MRCM
M&R Capital Management Summit, New Jersey $454M AUM 40.11% 1-Year Est. Return
HF
HRT Financial New York $40.1B AUM 58.22% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
BCM
Bridgeway Capital Management Houston, Texas $4.97B AUM 44.96% 1-Year Est. Return
TRCT
Tower Research Capital (TRC) New York $3.85B AUM 32.11% 1-Year Est. Return
First Manhattan
First Manhattan New York $36.1B AUM 11.5% 1-Year Est. Return
State Street
State Street Boston, Massachusetts $2.9T AUM 29.55% 1-Year Est. Return
Goldman Sachs
Goldman Sachs New York $871B AUM 31.28% 1-Year Est. Return

Moors & Cabot's SCPS Position: Q2 2022 in Review

Moors & Cabot sold out of Scopus BioPharma Inc. Common Stock (SCPS) in Q2 2022, closing a stake of 14,500 shares — an estimated $10K sold.

Moors & Cabot first reported a position in SCPS in Q1 2022 and held it in 1 quarter. The position peaked at $10K in Q1 2022. 17 funds tracked by Wall St. Rank hold SCPS as of Q2 2022.

  • Moors & Cabot reported no remaining Scopus BioPharma Inc. Common Stock position as of Q2 2022 after selling out during the quarter.
  • Moors & Cabot sold 14,500 Scopus BioPharma Inc. Common Stock shares in Q2 2022, an estimated $10K.
  • Moors & Cabot first reported a position in Scopus BioPharma Inc. Common Stock in Q1 2022 and held it in 1 quarter.
  • Moors & Cabot's Scopus BioPharma Inc. Common Stock position peaked at $10K in Q1 2022.
  • 17 funds tracked by Wall St. Rank held Scopus BioPharma Inc. Common Stock as of Q2 2022.

Based on Moors & Cabot's 13F filing for Q2 2022, filed 8 Aug 2022.